Patriot Financial Group Insurance Agency LLC Increases Stock Position in Charles River Laboratories International, Inc. $CRL

Patriot Financial Group Insurance Agency LLC grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 19.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,035 shares of the medical research company’s stock after acquiring an additional 329 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in Charles River Laboratories International were worth $309,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Lecap Asset Management Ltd. purchased a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at about $1,538,000. HB Wealth Management LLC purchased a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at about $306,000. V Square Quantitative Management LLC boosted its holdings in shares of Charles River Laboratories International by 50.1% during the 2nd quarter. V Square Quantitative Management LLC now owns 1,780 shares of the medical research company’s stock valued at $270,000 after acquiring an additional 594 shares during the last quarter. ORG Wealth Partners LLC boosted its holdings in shares of Charles River Laboratories International by 49.8% during the 2nd quarter. ORG Wealth Partners LLC now owns 496 shares of the medical research company’s stock valued at $77,000 after acquiring an additional 165 shares during the last quarter. Finally, Patton Fund Management Inc. purchased a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at about $291,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 1.3%

Charles River Laboratories International stock opened at $177.56 on Friday. The firm’s 50 day moving average price is $159.47 and its 200-day moving average price is $147.29. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $230.02. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The stock has a market cap of $8.74 billion, a P/E ratio of -133.51, a PEG ratio of 4.74 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. During the same period last year, the firm posted $2.80 earnings per share. Charles River Laboratories International’s revenue for the quarter was up .6% compared to the same quarter last year. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Citigroup upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. Wall Street Zen upgraded shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Monday, September 29th. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Saturday, September 27th. JPMorgan Chase & Co. increased their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. Finally, Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and increased their price objective for the stock from $142.00 to $195.00 in a research note on Tuesday, September 9th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $179.93.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction on Monday, August 18th. The shares were sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the transaction, the executive vice president directly owned 24,116 shares of the company’s stock, valued at $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).